[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation described is characteristic of anti-IgLON5 disease. This condition is a distinct neurological syndrome associated with antibodies against IgLON5, a neuronal cell adhesion molecule.\n\nKey features highlighted in the vignette include:\n1.  Sleep Dysfunction: The hallmark of anti-IgLON5 disease is a unique parasomnia characterized by the coexistence of non-REM and REM sleep behavior disorder (RBD). Patients often exhibit undifferentiated non-REM parasomnias and sleep-disordered breathing, specifically nocturnal stridor and obstructive sleep apnea.\n2.  Neurological Symptoms: Patients often develop gait instability, bulbar dysfunction (dysphagia, dysarthria), and mild cognitive decline. The gait instability can mimic progressive supranuclear palsy (PSP) or cerebellar ataxia.\n3.  Demographics and Course: It typically affects older adults and has a chronic, progressive course.\n\nLet's review the other options:\n*   Anti-Hu antibody: Associated with paraneoplastic encephalomyelitis and sensory neuronopathy, often linked to small cell lung cancer. It does not typically present with this specific sleep disorder profile.\n*   Anti-Yo antibody: Classically associated with paraneoplastic cerebellar degeneration (PCD). While the patient has gait instability and cerebellar atrophy, the prominent sleep disturbances and stridor are not characteristic of anti-Yo syndrome.\n*   Anti-Ma2 antibody: Associated with diencephalic, brainstem, and limbic encephalitis (often with testicular tumors). While it can cause excessive daytime sleepiness and RBD, the specific combination of stridor and complex non-REM/REM parasomnias points to anti-IgLON5.\n*   Anti-NMDA receptor antibody: Typically presents with psychiatric symptoms, seizures, movement disorders, and autonomic instability, and is more faster in onset than the 2-year history described here.\n\nTherefore, the specific constellation of symptoms—particularly the parasomnias and stridor—makes anti-IgLON5 the correct answer.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-002", "question": "A 32-year-old woman presents with irregular vaginal bleeding 18 months after an uncomplicated term delivery. Serum hCG is mildly elevated at 150 mIU/mL. Pelvic MRI demonstrates a 4 cm intrauterine mass. Endometrial biopsy reveals sheets of intermediate trophoblastic cells with eosinophilic cytoplasm, low mitotic index, and immunohistochemical staining strongly positive for hPL but negative for hCG. Which diagnosis is most likely?", "options": ["A) Choriocarcinoma", "B) Placental site trophoblastic tumor", "C) Epithelioid trophoblastic tumor", "D) Persistent hydatidiform mole", "E) Invasive mole"], "answer": "B", "answer_index": 1, "explanation": "Placental site trophoblastic tumor (PSTT) is a rare gestational trophoblastic disease derived from intermediate trophoblasts, characterized by hPL positivity and minimal hCG production. It presents months to years after pregnancy with mild hCG elevation and is relatively chemoresistant, often requiring hysterectomy. Choriocarcinoma and invasive mole have markedly elevated hCG and are hCG-positive on immunostain. Epithelioid trophoblastic tumor is even rarer and arises from chorionic-type intermediate trophoblasts.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Here is a step-by-step analysis to determine the correct diagnosis:\n\n1.  Patient History: The patient had an uncomplicated term delivery 18 months ago. While Gestational Trophoblastic Neoplasia (GTN) can follow any pregnancy event, Placental Site Trophoblastic Tumor (PSTT) and Epithelioid Trophoblastic Tumor (ETT) are the types most frequently associated with an interval of months to years following a term delivery.\n\n2.  Serum Markers: The serum hCG is mildly elevated (150 mIU/mL). This contrasts with choriocarcinoma and invasive moles, which typically present with rare exceptions with very high hCG levels (often >100,000 mIU/mL). PSTT and ETT produce low levels of hCG because they originate from intermediate trophoblasts rather than syncytiotrophoblasts (the primary hCG producers).\n\n3.  Histopathology: The biopsy shows sheets of intermediate trophoblastic cells with eosinophilic cytoplasm.\n    *   Choriocarcinoma is characterized by a dimorphic population of cytotrophoblasts and syncytiotrophoblasts.\n    *   Invasive mole shows the presence of chorionic villi.\n    *   PSTT and ETT are comprised of intermediate trophoblasts.\n\n4.  Immunohistochemistry (IHC): The tumor is strongly positive for hPL (human placental lactogen) and negative (or weak) for hCG.\n    *   PSTT: Arises from implantation site intermediate trophoblasts. The classic IHC profile is diffuse, strong positivity for hPL and weak/focal positivity for hCG.\n    *   ETT: Arises from chorionic-type intermediate trophoblasts. ETT typically stains positively for p63 and only focally for hPL.\n    *   Choriocarcinoma: Typically stains diffusely positive for hCG and only focally/weakly for hPL.\n\n5.  Conclusion: The combination of a tumor arising months after a term delivery, low serum hCG, sheets of intermediate trophoblasts, and strong hPL positivity is the textbook presentation for a Placental Site Trophoblastic Tumor.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-003", "question": "An 18-year-old male with genetically confirmed Danon disease (LAMP2 mutation) presents with severe hypertrophic cardiomyopathy (septal thickness 28 mm), ventricular pre-excitation (WPW pattern on ECG), and recurrent syncope. Electrophysiology study identifies three distinct accessory pathways. Despite maximal medical therapy, he continues to have pre-excited atrial fibrillation. What is the most appropriate next management step?", "options": ["A) Initiate flecainide therapy", "B) Perform catheter ablation of all accessory pathways", "C) Increase beta-blocker dosage", "D) Evaluate for heart transplantation", "E) Implant a dual-chamber pacemaker"], "answer": "D", "answer_index": 3, "explanation": "Danon disease causes rapidly progressive HCM, multiple accessory pathways, and skeletal myopathy with poor prognosis. Catheter ablation is often unsuccessful due to rapid pathway recurrence and progressive myocardial involvement. Beta-blockers and verapamil are contraindicated in WPW with pre-excited AF. Flecainide may transiently suppress pathways but doesn't alter disease course. Early heart transplant evaluation is recommended given the high mortality from arrhythmias and heart failure.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient has Danon disease, an X-linked dominant lysosomal storage disorder caused by LAMP2 mutations. The clinical presentation in males is characterized by severe hypertrophic cardiomyopathy (often with massive LVH, here 28 mm), ventricular pre-excitation (WPW pattern), and skeletal myopathy/intellectual disability.\n\nThe management features in this case point towards heart transplantation for several reasons:\n1.  Prognosis: In males with Danon disease, the cardiomyopathy progresses rapidly to end-stage heart failure and death. The average age of death without transplantation is approximately 19 years. This patient is 18 and already has severe phenotypic expression (28 mm thickness) and recurrent syncope, placing him at imminent risk of death.\n2.  Arrhythmia Refractoriness: The patient has multiple (three) accessory pathways and continues to have pre-excited atrial fibrillation despite maximal medical therapy. In Danon disease, the electrophysiological substrate is complex; accessory pathways can be multiple, and the massive hypertrophy and distinctive fibrosis/vacuolization make catheter ablation difficult with lower success rates and higher recurrence rates compared to the general population.\n3.  Holistic Management: While ablation is often attempted for symptom control, it does not alter the underlying progression of the cardiomyopathy which is the primary driver of mortality. Given the patient's age, severity of hypertrophy, and refractoriness of the arrhythmia (symptoms of advanced disease), the most definitive and appropriate management step is to move towards heart transplantation, which is the only curative therapy.\n\nOptions analysis:\n*   A: Flecainide is contraindicated in patients with structural heart disease (severe HCM).\n*   B: While ablation is the standard of care for WPW, the complexity (3 pathways, severe hypertrophy) and the underlying terminal nature of the cardiomyopathy in an 18-year-old male make transplantation the priority. Ablation may be futile or insufficient to prevent sudden death from the myopathy itself.\n*   C: Beta-blockers are already likely part of therapy, and increasing dosage may not control the accessory pathway conduction during AF and could be dangerous if it promotes AV block without blocking the AP.\n*   D: Evaluate for heart transplantation is the correct strategic step for an 18-year-old male with Danon disease and signs of decompensation/instability.\n*   E: A pacemaker does not address the lethal arrhythmia or pump failure.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-004", "question": "A 42-year-old woman with multiple sclerosis on natalizumab for 30 months develops subacute cognitive decline over 3 weeks. Her JCV antibody index is 2.8. Brain MRI reveals new non-enhancing subcortical white matter lesions without mass effect. CSF JCV PCR is positive. Which intervention is most critical to improve survival?", "options": ["A) Continue natalizumab with close monitoring", "B) Switch directly to ocrelizumab", "C) Initiate immediate plasma exchange", "D) Start mirtazapine 30 mg daily", "E) Begin mefloquine 250 mg weekly"], "answer": "C", "answer_index": 2, "explanation": "Natalizumab-associated progressive multifocal leukoencephalopathy requires immediate drug discontinuation and plasma exchange to rapidly clear the monoclonal antibody, preventing immune reconstitution inflammatory syndrome (IRIS) and improving survival. Continuing or switching immunosuppression is contraindicated. Mirtazapine and mefloquine have been investigated but lack evidence of benefit. Plasma exchange is the only intervention shown to alter mortality.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Based on the clinical presentation, MRI findings, and positive CSF JCV PCR, the patient has Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML).\n\n1.  Stop Natalizumab: The most critical step in management is to restore the immune system's ability to fight the JC virus by discontinuing the immunosuppressive agent.\n2.  Drug Removal: Natalizumab has a long half-life and high receptor saturation. Simply stopping the drug may result in retained biological effect for months. Plasma Exchange (PLEX) is commonly employed to accelerate the clearance of the drug (removing approximately 90% of the drug within 3–5 sessions), thereby allowing faster immune reconstitution (desaturation of alpha-4 integrin receptors).\n3.  IRIS Management: While rapid immune reconstitution carries the risk of Immune Reconstitution Inflammatory Syndrome (IRIS), restoring immunocompetence is necessary for survival. Treating physicians must monitor closely for IRIS (which typically occurs days to weeks after PLEX) and treat with corticosteroids if it develops.\n\nDiscussion of other options:\n*   A) Continue natalizumab: This would be fatal as it maintains the immunosuppression allowing viral replication.\n*   B) Switch directly to ocrelizumab: Switching to another potent immunosuppressant (anti-CD20) during an active opportunistic infection is contraindicated and would hinder the necessary immune response against the virus.\n*   D) Start mirtazapine: While mirtazapine (a 5-HT2a antagonist) has been proposed to inhibit viral entry into glial cells, clinical data has not consistently demonstrated benefit (or has shown lack of benefit), and it is not considered the critical intervention for survival compared to immune reconstitution.\n*   E) Begin mefloquine: Clinical trials (e.g., the AACT trial) showed that mefloquine was not effective in treating PML.\n\nTherefore, reducing the concentration of the offending agent via plasma exchange is the best answer among the choices provided to enable the immune system to combat the virus.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-005", "question": "A 58-year-old man presents with a 5-year history of chronic urticarial rash, recurrent fevers, debilitating bone pain, and monoclonal IgM kappa on serum protein electrophoresis. Symptoms are refractory to high-dose H1/H2 antihistamines. Laboratory studies reveal markedly elevated ESR and CRP. Which cytokine is the primary therapeutic target for this condition?", "options": ["A) Interleukin-1", "B) Interleukin-6", "C) Interleukin-17", "D) Tumor necrosis factor-alpha", "E) Interferon-gamma"], "answer": "A", "answer_index": 0, "explanation": "Schnitzler syndrome is an autoinflammatory disease driven by NLRP3 inflammasome activation with overproduction of IL-1β. Anakinra, an IL-1 receptor antagonist, is first-line therapy and induces rapid remission. While IL-6 and TNF-alpha may be elevated, they are not the primary pathogenic cytokines. IL-17 and interferon-gamma are not central to the disease mechanism.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with a constellation of symptoms consistent with Schnitzler syndrome, an acquired autoinflammatory disorder. The key features include:\n\n1.  Chronic urticarial rash: Typically non-pruritic or minimally pruritic and does not respond well to antihistamines (indicating a neutrophilic rather than histaminergic process).\n2.  Monoclonal gammopathy: Specifically IgM kappa is the classic finding.\n3.  Systemic inflammation: Recurrent fevers, elevated ESR, and CRP.\n4.  Bone pain: Often affecting the tibiae or iliac crests, caused by osteosclerosis or bone remodeling.\n\nThe pathophysiology of Schnitzler syndrome involves the abnormal activation of the innate immune system, specifically the NLRP3 inflammasome, leading to excessive production of Interleukin-1 beta (IL-1$\\beta$). Consequently, agents that block IL-1, such as anakinra (an IL-1 receptor antagonist) or canakinumab (a monoclonal antibody against IL-1$\\beta$), are highly effective and considered the treatment of choice. Patients typically do not respond well to corticosteroids, colchicine, or TNF-alpha inhibitors, and antihistamines are ineffective.\n\nTherefore, the primary therapeutic target is Interleukin-1.\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-006", "question": "A 35-year-old man with bilateral juvenile cataracts, progressive Achilles tendon xanthomas, and cerebellar ataxia is diagnosed with cerebrotendinous xanthomatosis. Serum cholestanol level is markedly elevated. Which treatment modality has been shown to halt neurologic progression in this disorder?", "options": ["A) High-intensity statin therapy", "B) Chenodeoxycholic acid supplementation", "C) Weekly LDL apheresis", "D) Ezetimibe monotherapy", "E) Coenzyme Q10 supplementation"], "answer": "B", "answer_index": 1, "explanation": "Cerebrotendinous xanthomatosis results from CYP27A1 deficiency, causing cholestanol accumulation in neural tissue. Chenodeoxycholic acid inhibits cholesterol 7α-hydroxylase, reducing cholestanol synthesis and stabilizing neurologic function. Statins, ezetimibe, and LDL apheresis do not effectively lower central nervous system cholestanol. Coenzyme Q10 is used for mitochondrial disorders, not this condition.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Reflecting on the clinical presentation, the patient has the classic triad of cerebrotendinous xanthomatosis (CTX): premature cataracts (often in childhood), tendon xanthomas (particularly the Achilles tendon), and progressive neurologic dysfunction (cerebellar ataxia in this case). The elevated serum cholestanol confirms the diagnosis.\n\nCTX is an autosomal recessive disorder caused by mutations in the *CYP27A1* gene, leading to a deficiency of the mitochondrial enzyme sterol 27-hydroxylase. This enzyme is crucial in the bile acid synthesis pathway. Its deficiency leads to a block in the formation of chenodeoxycholic acid (CDCA) and cholic acid. Due to the lack of CDCA, there is a loss of negative feedback on the rate-limiting enzyme cholesterol 7$\\alpha$-hydroxylase (CYP7A1). This results in the overproduction and accumulation of cholestanol and bile alcohol precursors in tissues.\n\nThe standard and most effective treatment for CTX is replacement therapy with chenodeoxycholic acid (CDCA). Exogenous CDCA restores the negative feedback loop on CYP7A1, thereby suppressing the abnormal production of cholestanol and bile alcohols. Long-term treatment with CDCA has been demonstrated to normalize serum cholestanol levels and, importantly, can stabilize or improve neurologic symptoms and prevent further progression, especially when initiated early.\n\nWhile HMG-CoA reductase inhibitors (statins) can be used as adjunctive therapy to further lower cholestanol, they do not address the lack of bile acid feedback inhibition as effectively as CDCA does on its own. LDL apheresis and ezetimibe are not the primary disease-modifying treatments for the neurologic sequelae of CTX.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-007", "question": "A 16-year-old girl presents with cyclic, worsening right pelvic pain for 6 months, occurring with each menses. She reports normal menstrual bleeding. Pelvic ultrasound reveals a didelphic uterus with a 5 cm right hematocolpos and a normal left uterine horn. Renal ultrasound demonstrates absence of the right kidney. Which congenital anomaly best explains this presentation?", "options": ["A) Mayer-Rokitansky-Küster-Hauser syndrome", "B) OHVIRA syndrome", "C) Complete androgen insensitivity syndrome", "D) Transverse vaginal septum", "E) Imperforate hymen"], "answer": "B", "answer_index": 1, "explanation": "OHVIRA (Obstructed Hemivagina with Ipsilateral Renal Agenesis) syndrome is characterized by a didelphic uterus with obstructed hemivagina causing hematocolpos and ipsilateral renal agenesis. Patients have normal menses from the patent uterine horn. MRKH syndrome involves uterine agenesis. CAIS affects 46,XY individuals. Transverse vaginal septum and imperforate hymen occur with a normal uterus and kidneys.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical presentation describes a triad of:\n1.  Uterus didelphys (double uterus).\n2.  Obstructed hemivagina (indicated by the right hematocolpos and cyclic pain, while normal menses occur from the unobstructed left side).\n3.  Ipsilateral renal agenesis (absence of the right kidney, ipsilateral to the obstruction).\n\nThis specific triad is the hallmark definition of OHVIRA syndrome (Obstructed Hemivagina and Ipsilateral Renal Agenesis), also known as Herlyn-Werner-Wunderlich syndrome.\n\n*   Mayer-Rokitansky-Küster-Hauser syndrome (A) involves aplasia of the uterus and upper vagina, presenting with primary amenorrhea, not a didelphic uterus with menstruation.\n*   Complete androgen insensitivity syndrome (C) presents with a 46,XY karyotype, absence of a uterus, and primary amenorrhea.\n*   Transverse vaginal septum (D) and Imperforate hymen (E) are outflow tract obstructions. If complete, they typically result in primary amenorrhea with hematocolpos/hematometra. While a septum is involved in OHVIRA, it is specifically a longitudinal vaginal septum causing unilateral obstruction in the setting of a didelphic uterus, making \"OHVIRA syndrome\" the specific and best diagnosis for the syndromic presentation including renal agenesis.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-008", "question": "A 62-year-old man with a HeartMate 3 left ventricular assist device presents with acute onset of dark urine, fatigue, and dizziness. Laboratory studies demonstrate LDH 2,800 U/L and plasma free hemoglobin 80 mg/dL. Device interrogation shows increased power consumption with intermittent spikes. Transthoracic echocardiography suggests inflow cannula obstruction. What is the most appropriate immediate management?", "options": ["A) Increase warfarin target INR to 3.5-4.0", "B) Initiate intravenous unfractionated heparin infusion", "C) Administer intraventricular alteplase 25 mg", "D) Deliver intrapump alteplase 10 mg via percutaneous catheter", "E) Proceed to emergent surgical pump exchange"], "answer": "D", "answer_index": 3, "explanation": "HeartMate 3 pump thrombosis is managed with low-dose intrapump alteplase (10 mg) delivered via percutaneous catheter directly into the device, which has shown high success rates. Systemic thrombolysis or intraventricular administration risks hemorrhagic stroke. Increasing anticoagulation is insufficient for established thrombosis. Surgical exchange is reserved for thrombolysis failure or hemodynamic collapse.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient with a HeartMate 3 (HM3) left ventricular assist device (LVAD) presents with signs and symptoms classically suggestive of pump thrombosis.\n\n1.  Diagnosis:\n    *   Clinical: Dark urine (hemoglobinuria), fatigue, dizziness.\n    *   Labs: Significantly elevated LDH (2,800 U/L) and plasma free hemoglobin (80 mg/dL), indicating severe hemolysis.\n    *   Device Interrogation: Increased power consumption with intermittent spikes. In the specific context of HeartMate 3 (a magnetically levitated centrifugal pump), power spikes are a hallmark sign of thrombus ingestion or formation within the pump impellers causing friction.\n    *   Echocardiography: Suggests inflow cannula obstruction. While this can be caused by pannus or malposition, the acute onset, severe hemolysis, and power spikes strongly point to a thrombotic obstruction (clot).\n\n2.  Management Options:\n    *   A) Increase warfarin: This is a long-term preventive strategy and is inadequate for acute severe thrombosis with hemolysis.\n    *   B) Intravenous unfractionated heparin: While initiating heparin is the standard *initial* step for suspected pump thrombosis, in cases with signs of severe hemolysis (hemoglobinuria, very high LDH) and \"inflow cannula obstruction\" involving a thrombus, heparin alone is often insufficient to resolve the clot and prevent renal failure or pump stop. It prevents propagation but does not actively dissolve the thrombus.\n    *   C) Intraventricular alteplase: While lytics are indicated, intraventricular administration is less targeted than intrapump delivery and the dose (25 mg) is higher than typically used for local protocols (higher bleeding risk).\n    *   E) Emergent surgical pump exchange: This is the definitive treatment for refractory thrombosis or hemodynamic instability (cardiogenic shock). However, it carries significant morbidity and mortality (redo sternotomy). If the patient is hemodynamically stable (dizziness alone does not constitute shock), a trial of lytic therapy is often preferred to avoid surgery.\n    *   D) Deliver intrapump alteplase 10 mg via percutaneous catheter: Recent literature and advanced management protocols support the use of catheter-directed (\"local\" or \"direct\") thrombolysis for LVAD pump thrombosis, particularly for obstruction at the inflow or within the pump. This method delivers a high concentration of the drug directly to the clot with a lower total dose (e.g., 10-20 mg) compared to systemic administration, reducing the risk of bleeding while effectively resolving the thrombosis. Given the \"inflow cannula obstruction\" and acute thrombotic nature, this targeted therapy is the most appropriate, sophisticated *immediate* intervention to resolve the hemolysis and obstruction in a stable patient.\n\nTherefore, the specific, minimally invasive, and active treatment for this severe thrombotic event is catheter-directed thrombolysis.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient is a 55-year-old immunocompetent gardener presenting with a subacute neurologic decline, focal signs, and multiple ring-enhancing lesions on MRI. The CSF shows a lymphocytic pleocytosis with negative standard cultures (bacterial/fungal/AFB).\n\n1.  Diagnosis: The clinical triad of an immunocompetent host with significant soil exposure (gardener), subacute subacute granulomatous encephalitis, and ring-enhancing lesions is highly suggestive of Granulomatous Amebic Encephalitis (GAE) caused by _Balamuthia mandrillaris_ or _Acanthamoeba_ spp.\n    *   _Balamuthia mandrillaris_ is a free-living amoeba found in soil. Infection typically occurs through skin wounds or inhalation of dust (hence the \"gardener\" clue). It often affects immunocompetent individuals (unlike _Acanthamoeba_, which more commonly affects the immunocompromised, though it can affect competent hosts).\n    *   The disease course is subacute to chronic.\n    *   Imaging typically displays multiple ring-enhancing lesions with surrounding edema, mimicking metastatic cancer or abscesses.\n    *   Routine cultures do not detect amoebas; diagnosis often requires specific PCR or observation on biopsy.\n\n2.  Treatment: GAE has a high mortality rate and is difficult to treat. The Centers for Disease Control and Prevention (CDC) recommends combination therapy.\n    *   Miltefosine is a critical component of the regimen for free-living amebas (including _Balamuthia_, _Acanthamoeba_, and _Naegleria_). It was originally an anti-leishmaniasis drug.\n    *   Other drugs commonly included in the cocktail for _Balamuthia_ are albendazole, fluconazole, flucytosine, azithromycin, and sulfadiazine.\n    *   Therefore, the combination of Albendazole plus miltefosine (Option B) is the most appropriate empiric therapy targeting this etiology among the choices provided.\n\n3.  Ruling out other options:\n    *   A) Liposomal amphotericin B: Used for fungal infections or Primary Amebic Meningoencephalitis (PAM) caused by _Naegleria fowleri_. PAM is acute/fulminant (death within days), associated with warm fresh water swimming, and usually shows purulent (neutrophilic) meningitis, not subacute ring-enhancing lesions.\n    *   C) Vancomycin plus ceftriaxone plus dexamethasone: This is standard empiric therapy for acute bacterial meningitis. The subacute course (3 weeks), lymphocytic CSF, and imaging findings are not consistent with acute bacterial meningitis.\n    *   D) Ganciclovir plus foscarnet: Treatment for Cytomegalovirus (CMV) encephalitis. This is typically seen in severely immunocompromised patients (e.g., AIDS with CD4 < 50), and MRI findings usually show ventriculoencephalitis rather than ring-enhancing lesions.\n    *   E) Voriconazole: Treatment of choice for invasive Aspergillosis. While CNS aspergillosis can cause ring-enhancing lesions, it is very rare in immunocompetent patients without specific risk factors (e.g., endocarditis, neurosurgery, contiguous sinusitis). The \"gardener\" clue points more specifically toward soil-transmitted amoebas in the context of encephalitis.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-010", "question": "An 8-year-old boy presents with recurrent fevers, livedo racemosa, recurrent lacunar strokes, and vasculitic neuropathy. Laboratory studies show low IgM, elevated IgA, and negative ANCA. Genetic testing confirms biallelic loss-of-function mutations in ADA2. Which biologic therapy is most effective for this condition?", "options": ["A) High-dose systemic glucocorticoids", "B) Intravenous cyclophosphamide", "C) Etanercept", "D) Anakinra", "E) Rituximab"], "answer": "C", "answer_index": 2, "explanation": "DADA2 (Deficiency of Adenosine Deaminase 2) causes vasculitis due to loss of ADA2 enzyme function, leading to macrophage polarization defects and TNF-alpha overproduction. Etanercept, a TNF-alpha inhibitor, is highly effective and can induce remission. Cyclophosphamide and steroids are less effective. Anakinra has variable response, and rituximab is ineffective as the disease is not B-cell mediated.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation described in the question—recurrent fevers, livedo racemosa, recurrent lacunar strokes, vasculitic neuropathy, low IgM, and biallelic loss-of-function mutations in *ADA2*—is diagnostic of Deficiency of Adenosine Deaminase 2 (DADA2).\n\nDADA2 is a monogenic autoinflammatory disorder promoting a vasculopathy that resembles polyarteritis nodosa (PAN). The underlying pathophysiology involves the polarization of macrophages toward a pro-inflammatory M1 phenotype, resulting in excessive production of tumor necrosis factor-alpha (TNF-alpha). Unlike classical PAN, the vasculopathy and stroke risk in DADA2 are often resistant to standard immunosuppressive regimens such as corticosteroids, cyclophosphamide, or azathioprine.\n\nClinical studies and case series have demonstrated that TNF inhibitors (such as etanercept, adalimumab, or infliximab) are the most effective medical therapy for controlling the systemic inflammation and, crucially, for preventing the recurrent ischemic strokes associated with this condition. Hematopoietic stem cell transplantation (HSCT) is considered for patients with severe bone marrow failure or profound immunodeficiency, but anti-TNF therapy is the first-line biologic treatment for the vasculitic phenotype.\n\nA - Glucocorticoids may control fever but do not reliably prevent strokes.\nB - Cyclophosphamide may be used in severe vasculitis but is less effective than anti-TNF agents for the specific prevention of strokes in DADA2.\nD - Anakinra targets IL-1, which is not the primary driver in DADA2 (unlike in cryopyrin-associated periodic syndromes).\nE - Rituximab targets B-cells. Since DADA2 patients frequently have low immunoglobulins and B-cell dysfunction, and the disease is macrophage-driven, this is not the preferred therapy.\n\nThe answer is (C)"}]